Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

被引:12
|
作者
Sugiura, Ayumi [1 ]
Joshita, Satoru [1 ]
Yamashita, Yuki [1 ]
Yamazaki, Tomoo [1 ]
Fujimori, Naoyuki [1 ]
Kimura, Takefumi [1 ]
Matsumoto, Akihiro [1 ,2 ]
Wada, Shuichi [3 ]
Mori, Hiromitsu [3 ]
Shibata, Soichiro [3 ]
Yoshizawa, Kaname [4 ]
Morita, Susumu [4 ]
Furuta, Kiyoshi [5 ]
Kamijo, Atsushi [5 ]
Iijima, Akihiro [6 ]
Kako, Satoko [6 ]
Maruyama, Atsushi [7 ]
Kobayashi, Masakazu [8 ]
Komatsu, Michiharu [8 ]
Matsumura, Makiko [9 ]
Miyabayashi, Chiharu [10 ]
Ichijo, Tetsuya [11 ]
Takeuchi, Aki [12 ]
Koike, Yuriko [13 ]
Gibo, Yukio [14 ]
Tsukadaira, Toshihisa [15 ]
Inada, Hiroyuki [16 ]
Nakano, Yoshiyuki [17 ]
Usuda, Seiichi [18 ]
Kiyosawa, Kendo [18 ]
Tanaka, Eiji [19 ]
Umemura, Takeji [1 ,20 ]
机构
[1] Shinshu Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[2] Shinshu Univ Hosp, Consultat Ctr Hepat Dis, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[3] Japanese Red Cross Soc Nagano Hosp, Dept Gastroenterol, 22-1 Wakasato, Nagano, Nagano 3800928, Japan
[4] Natl Hosp Org, Shinshu Ueda Med Ctr, Dept Gastroenterol, 27-21 Midorigaoka, Ueda, Nagano 3868610, Japan
[5] Natl Hosp Org, Matsumoto Med Ctr, Dept Gastroenterol, 20-30 Muraimachiminami, Matsumoto, Nagano 3998701, Japan
[6] Nagano Prefectural Kiso Hosp, Dept Internal Med, 6613-4 Fukushima, Kiso, Nagano 3978555, Japan
[7] Ina Cent Hosp, Dept Gastroenterol, 1313-1 Koshiroukubo, Ina, Nagano 3968555, Japan
[8] Japanese Red Cross Soc Suwa Hosp, Dept Gastroenterol, 5-11-50 Kogandori, Suwa, Nagano 3928510, Japan
[9] Nagano Chuo Hosp, Dept Gastroenterol, 1570 Tsuruga Nishitsurugamachi, Nagano, Nagano 3800814, Japan
[10] Chikuma Cent Hosp, Dept Gastroenterol, 58 Kuiseshita, Chikuma, Nagano 3870011, Japan
[11] Japanese Red Cross Soc Azumino Hosp, Dept Gastroenterol, 5685 Toyoshina, Azumino, Nagano 3998205, Japan
[12] Aki Naika Clin, 236-1 Nozawa, Saku, Nagano 3850053, Japan
[13] Kawanakajima Clin, 1942-25 Kawanagajima Machi, Nagano, Nagano 3812221, Japan
[14] Gibo Hepatol Clin, 1-34-20 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[15] Kenwakai Hosp, Dept Gastroenterol, 1936 Kanaenakadaira, Iida, Nagano 3958522, Japan
[16] Kanebako Internal Med Clin, 320-2 Kanebako, Nagano, Nagano 3810007, Japan
[17] Nakano Gastroenterol Clin, 4-13-5 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[18] Aizawa Hosp, Gastroenterol Ctr, 2-5-1 Honjo, Matsumoto, Nagano 3900814, Japan
[19] Shinshu Univ, Dept Community Med Promot, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[20] Shinshu Univ, Inst Biomed Sci, Dept Life Innovat, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
基金
日本学术振兴会;
关键词
chronic hepatitis C; hepatitis C virus; glecaprevir; pibrentasvir; retreatment; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; LIVER-BIOPSY; GENOTYPE; HCV; FIBROSIS;
D O I
10.3390/biomedicines8040074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
    Wyles, D.
    Weiland, O.
    Yao, B.
    Reindollar, R.
    Weilert, F.
    Dufour, JF.
    Gordon, S. C.
    Poordad, F.
    Stoehr, A.
    Brown, A.
    Mauss, S.
    Samanta, S.
    Pilot-Matias, T.
    Jr, L. R.
    Trinh, R.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S23 - S24
  • [32] Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis
    Cornberg, Markus
    Negro, Francesco
    Lampertico, Pietro
    Turnes, Juan
    Curry, Michael P.
    Brown, Ashley
    Wedemeyer, Heiner
    Carrion, Jose A.
    Wick, Nicole
    Pangerl, Andreas
    Larsen, Lois
    Yu, Yao
    Persico, Marcello
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S600 - S600
  • [33] Real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: updated data from the German Hepatitis C-Registry
    Cornberg, M.
    Naumann, U.
    Stoehr, A.
    Sick, C.
    Teuber, G.
    Schiffelholz, W.
    Mauss, S.
    Lohmann, K.
    Kleine, H.
    Pangerl, A.
    Mueller, T.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 197 - 198
  • [34] Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study
    Beisel, Claudia
    Herrmann, Marissa
    Piecha, Felix
    Lampalzer, Sibylle
    Buescher, Gustav
    Pischke, Sven
    Wiesch, Julian Schulze zur
    HEPATITIS MONTHLY, 2021, 21 (01)
  • [35] First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry
    Berg, T.
    Naumann, U.
    Stoehr, A.
    Sick, C.
    Teuber, G.
    Schiffelholz, W.
    Mauss, S.
    Hettinger, J.
    Kleine, H.
    Pangerl, A.
    Niederau, C.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S37 - S37
  • [36] Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
    Wyles, David
    Weiland, Ola
    Yao, Betty
    Weilert, Frank
    Dufour, Jean-Francois
    Gordon, Stuart C.
    Stoehr, Albrecht
    Brown, Ashley
    Mauss, Stefan
    Zhang, Zhenzhen
    Pilot-Matias, Tami
    Rodrigues, Lino, Jr.
    Mensa, Federico J.
    Poordad, Fred
    JOURNAL OF HEPATOLOGY, 2019, 70 (05) : 1019 - 1023
  • [37] RETREATMENT OF HEPATITIS C VIRUS-INFECTED PATIENTS WHO FAILED GLECAPREVIR/PIBRENTASVIR
    Weilert, Frank
    Tang, Hong
    Yao, Betty
    Lin, Minghua
    Mao, Qing
    Skoien, Richard
    Paik, Seung Woon
    Xie, Wen
    Tripathi, Rakesh
    Zhang, Zhenzhen
    Burroughs, Margaret
    Gane, Edward J.
    HEPATOLOGY, 2021, 74 : 601A - 601A
  • [38] Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
    Wyles, David
    Weiland, Ola
    Yao, Betty
    Reindollar, Robert
    Weilert, Frank
    Dufour, Jean-Francois
    Gordon, Stuart
    Poordad, Fred
    Stoehr, Albrecht
    Brown, Ashley
    Mauss, Stefan
    Samanta, Suvajit
    Pilot-Matias, Tami
    Rodrigues, Lino, Jr.
    Trinh, Roger
    SWISS MEDICAL WEEKLY, 2018, 148 : 25S - 25S
  • [39] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis (vol 41, pg 744, 2024)
    Lu, Mei
    Rupp, Loralee B.
    Melkonian, Christina
    Trudeau, Sheri
    Daida, Yihe G.
    Schmidt, Mark A.
    Gordon, Stuart C.
    ADVANCES IN THERAPY, 2024, 41 (06) : 2534 - 2535
  • [40] RETREATMENT OF PATIENTS WHO FAILED GLECAPREVIR/PIBRENTASVIR TREATMENT FOR HEPATITIS C VIRUS INFECTION
    Wyles, David L.
    Weiland, Ola
    Yao, Betty B.
    Reindollar, Robert
    Weilert, Frank
    Dufour, Jean-Francois
    Gordon, Stuart C.
    Poordad, Fred
    Stoehr, Albrecht
    Brown, Ashley S.
    Mauss, Stefan
    Samanta, Suvajit
    Pilot-Matias, Tami
    Rodrigues, Lino
    Trinh, Roger N.
    GASTROENTEROLOGY, 2018, 154 (06) : S1082 - S1082